Review

goat polyclonal anti gipc antibody (Santa Cruz Biotechnology)

Santa Cruz Biotechnology is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Santa Cruz Biotechnology goat polyclonal anti gipc antibody
Goat Polyclonal Anti Gipc Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gipc+antibody/us12397037-1175-11-20?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 26 article reviews

goat polyclonal anti gipc antibody - by Bioz Stars, 2026-07

93/100 stars

Images

Image Search Results

GIPC1 expression is diminished in colorectal cancer and correlates with unfavorable prognosis. (A) Volcano plots illustrate differentially expressed genes (DEGs) from the datasets GSE25070 , GSE32323 , GSE11353, GSE54986 , and GSE181722 . (B) Venn diagrams illustrating the overlapping DEGs across the datasets GSE25070 , GSE32323 , GSE11353, GSE54986 , and GSE181722 . (C) mRNA expression levels of GIPC1. (D) IHC staining detecting GIPC1 expression in colorectal cancer tissue microarray (TMA), which includes matched adjacent non-malignant tissue and colorectal cancer tissue. Scale bars are shown in Figure . (E) Scoring of GIPC1 expression in IHC data (n = 94). (F) Protein expression levels of GIPC1 in CRC tissue compared to matched normal tissue adjacent cancer (n = 11). (G) Kaplan-Meier survival analysis examining the relationship between GIPC1 expression and OS in CRC patients with pathological stages T1 and T2 in the TCGA database. (H) Receiver operating characteristic (ROC) curve evaluating the diagnostic value of GIPC1 for CRC. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 expression is diminished in colorectal cancer and correlates with unfavorable prognosis. (A) Volcano plots illustrate differentially expressed genes (DEGs) from the datasets GSE25070 , GSE32323 , GSE11353, GSE54986 , and GSE181722 . (B) Venn diagrams illustrating the overlapping DEGs across the datasets GSE25070 , GSE32323 , GSE11353, GSE54986 , and GSE181722 . (C) mRNA expression levels of GIPC1. (D) IHC staining detecting GIPC1 expression in colorectal cancer tissue microarray (TMA), which includes matched adjacent non-malignant tissue and colorectal cancer tissue. Scale bars are shown in Figure . (E) Scoring of GIPC1 expression in IHC data (n = 94). (F) Protein expression levels of GIPC1 in CRC tissue compared to matched normal tissue adjacent cancer (n = 11). (G) Kaplan-Meier survival analysis examining the relationship between GIPC1 expression and OS in CRC patients with pathological stages T1 and T2 in the TCGA database. (H) Receiver operating characteristic (ROC) curve evaluating the diagnostic value of GIPC1 for CRC. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Expressing, Immunohistochemistry, Microarray, Diagnostic Assay

GIPC1 inhibits chemotherapy resistance, growth, and metastasis. (A) Overexpression of GIPC1 in DLD1 cells (left) and knockdown of GIPC1 using three independent shRNAs in DLD1 cells (right). (B) Viability of DLD1 cells after exposure to varying concentrations of 5-FU. (C-E) CCK8 and colony formation assays demonstrating the proliferation ability of DLD1 cells. (F) Representative images of tumors from each mouse group (n = 6). DLD1 cells were injected subcutaneously into nude mice. (G) Tumor volume and weight were measured (n = 6). (H-I) Immunofluorescence (IF, H) and immunohistochemistry (IHC, I) staining of tumor sections from various groups. Scale bar = 50 µm. (J-K) Transwell assays assessing the migration and invasion capabilities. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 inhibits chemotherapy resistance, growth, and metastasis. (A) Overexpression of GIPC1 in DLD1 cells (left) and knockdown of GIPC1 using three independent shRNAs in DLD1 cells (right). (B) Viability of DLD1 cells after exposure to varying concentrations of 5-FU. (C-E) CCK8 and colony formation assays demonstrating the proliferation ability of DLD1 cells. (F) Representative images of tumors from each mouse group (n = 6). DLD1 cells were injected subcutaneously into nude mice. (G) Tumor volume and weight were measured (n = 6). (H-I) Immunofluorescence (IF, H) and immunohistochemistry (IHC, I) staining of tumor sections from various groups. Scale bar = 50 µm. (J-K) Transwell assays assessing the migration and invasion capabilities. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Over Expression, Knockdown, Injection, Immunofluorescence, Immunohistochemistry, Staining, Migration

GIPC1 interacts with TTC7B. (A) GIPC1 interacting proteins. (B) Overexpression of GIPC1-Flag and/or TTC7B-GFP in 293T cells, followed by Co-IP of cell lysates using anti-DDDDK-Tag (Flag) or anti-GFP-Tag antibodies. (C-D) Co-IP confirming the interaction between GIPC1 and TTC7B. (E) IF assessment of GIPC1 and TTC7B localization in cells. Scale bars are shown in Figure . (F) Exogenous GIPC1 interacts with TTC7B. Purified TTC7B-GFP from 293T cells was incubated with either purified recombinant GIPC1-GST or GST. After GST pull-down assays, the interaction between TTC7B protein and GIPC1 was analyzed. (G) GIPC1 fragments were used in experiments. (H) GIPC1-Flag fragments and TTC7B-GFP were co-transfected into 293T cells, followed by Co-IP using Flag beads to isolate the proteins. (I) Diagram illustrating the predicted binding sites between GIPC1 and TTC7B.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 interacts with TTC7B. (A) GIPC1 interacting proteins. (B) Overexpression of GIPC1-Flag and/or TTC7B-GFP in 293T cells, followed by Co-IP of cell lysates using anti-DDDDK-Tag (Flag) or anti-GFP-Tag antibodies. (C-D) Co-IP confirming the interaction between GIPC1 and TTC7B. (E) IF assessment of GIPC1 and TTC7B localization in cells. Scale bars are shown in Figure . (F) Exogenous GIPC1 interacts with TTC7B. Purified TTC7B-GFP from 293T cells was incubated with either purified recombinant GIPC1-GST or GST. After GST pull-down assays, the interaction between TTC7B protein and GIPC1 was analyzed. (G) GIPC1 fragments were used in experiments. (H) GIPC1-Flag fragments and TTC7B-GFP were co-transfected into 293T cells, followed by Co-IP using Flag beads to isolate the proteins. (I) Diagram illustrating the predicted binding sites between GIPC1 and TTC7B.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Over Expression, Co-Immunoprecipitation Assay, Purification, Incubation, Recombinant, Transfection, Binding Assay

GIPC1 stabilizes TTC7B protein by downregulating TRIM21 expression to reduce TTC7B ubiquitination. (A) qRT-PCR analysis of GIPC1 mRNA and TTC7B mRNA expression in GIPC1 knockdown DLD1 and SW480 cells. (B) Knockdown of GIPC1 in colorectal cancer cells, followed by examination of TTC7B protein levels. (C-D) DLD1 and SW480 cells treated with or without MG132 (20 µM) for 4 hours, followed by analysis of TTC7B expression. (E-F) DLD1 and SW480 cells treated with cycloheximide (CHX, 100 mg/mL) for varying time intervals, followed by assessment of TTC7B protein levels. Quantitative analysis of TTC7B expression relative to GAPDH. (G-H) GIPC1 inhibits TTC7B ubiquitination. Co-transfection of TTC7B-GFP, ubiquitin-HA, and/or GIPC1-Flag into 293T and DLD1 cells, treated with MG132 (20 μM) for 4 hours. Analysis of TTC7B ubiquitination levels. (I) Co-IP validating the interaction between TTC7B and Screened E3 ubiquitin ligases. (J) Analysis of TTC7B expression in TRIM21 knockdown DLD1 cells. (K) Analysis of TRIM21 expression in GIPC1 knockdown DLD1 cells. (L) Co-IP validating the interaction between GIPC1 and TRIM21. (M) Verify the interaction of TRIM21 with GIPC1 and TTC7B, respectively. (N) Cellular IF evaluating the localization of TRIM21 with GIPC1 and TTC7B in cells, respectively. Scale bar = 10 µm. Data are presented as mean ± SD. ***P < 0.001.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 stabilizes TTC7B protein by downregulating TRIM21 expression to reduce TTC7B ubiquitination. (A) qRT-PCR analysis of GIPC1 mRNA and TTC7B mRNA expression in GIPC1 knockdown DLD1 and SW480 cells. (B) Knockdown of GIPC1 in colorectal cancer cells, followed by examination of TTC7B protein levels. (C-D) DLD1 and SW480 cells treated with or without MG132 (20 µM) for 4 hours, followed by analysis of TTC7B expression. (E-F) DLD1 and SW480 cells treated with cycloheximide (CHX, 100 mg/mL) for varying time intervals, followed by assessment of TTC7B protein levels. Quantitative analysis of TTC7B expression relative to GAPDH. (G-H) GIPC1 inhibits TTC7B ubiquitination. Co-transfection of TTC7B-GFP, ubiquitin-HA, and/or GIPC1-Flag into 293T and DLD1 cells, treated with MG132 (20 μM) for 4 hours. Analysis of TTC7B ubiquitination levels. (I) Co-IP validating the interaction between TTC7B and Screened E3 ubiquitin ligases. (J) Analysis of TTC7B expression in TRIM21 knockdown DLD1 cells. (K) Analysis of TRIM21 expression in GIPC1 knockdown DLD1 cells. (L) Co-IP validating the interaction between GIPC1 and TRIM21. (M) Verify the interaction of TRIM21 with GIPC1 and TTC7B, respectively. (N) Cellular IF evaluating the localization of TRIM21 with GIPC1 and TTC7B in cells, respectively. Scale bar = 10 µm. Data are presented as mean ± SD. ***P < 0.001.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Expressing, Ubiquitin Proteomics, Quantitative RT-PCR, Knockdown, Cotransfection, Co-Immunoprecipitation Assay

GIPC1 inhibits proliferation, migration, and invasion by regulating TTC7B. (A) Overexpression of TTC7B in GIPC1 knockdown DLD1 and SW480 cells. (B-C) CCK8 and colony formation assays assessed proliferation capability. (D-E) Transwell assays evaluated the migration and invasion capabilities of DLD1 and SW480 cells. (F) Overexpression of TTC7B in GIPC1 knockdown DLD1 and SW480 cells, followed by analysis of mTOR, NF-κB, and their phosphorylation levels. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 inhibits proliferation, migration, and invasion by regulating TTC7B. (A) Overexpression of TTC7B in GIPC1 knockdown DLD1 and SW480 cells. (B-C) CCK8 and colony formation assays assessed proliferation capability. (D-E) Transwell assays evaluated the migration and invasion capabilities of DLD1 and SW480 cells. (F) Overexpression of TTC7B in GIPC1 knockdown DLD1 and SW480 cells, followed by analysis of mTOR, NF-κB, and their phosphorylation levels. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Migration, Over Expression, Knockdown, Phospho-proteomics

GIPC1 reverses chemoresistance through TTC7B in colorectal cancer. (A) Cell viability of DLD1 and SW480 cells after exposure to varying concentrations of 5-FU. (B) Schematic diagram of 5-FU treatment in a colorectal cancer xenograft animal model. (C) Representative images of neoplasms obtained from each mouse group (n = 8). (D-F) Tumor volume and weight measurements (n = 8). (G) H&E and IHC staining of tumor sections from various groups. Scale bar = 50 µm. (H) GIPC1 and Ki67 positive area in tumor sections from different groups. Data are presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: GIPC1 reverses chemoresistance through TTC7B in colorectal cancer. (A) Cell viability of DLD1 and SW480 cells after exposure to varying concentrations of 5-FU. (B) Schematic diagram of 5-FU treatment in a colorectal cancer xenograft animal model. (C) Representative images of neoplasms obtained from each mouse group (n = 8). (D-F) Tumor volume and weight measurements (n = 8). (G) H&E and IHC staining of tumor sections from various groups. Scale bar = 50 µm. (H) GIPC1 and Ki67 positive area in tumor sections from different groups. Data are presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Animal Model, Immunohistochemistry

The antitumor function of GIPC1-LNPs in chemotherapy-resistant CDX models. (A) Schematic representation of the synthesis of lipid nanoparticles (LNPs) delivering GIPC1 mRNA. (B) Average dimensions, PDI, and zeta potential of GIPC1-LNPs. (C) TEM images of GIPC1-LNPs. Scale bar = 100 nm. (D) Schematic diagram of GIPC1-LNPs treatment in colorectal cancer CDX animal models. (E) Representative images of tumors from each mouse group (n = 5). (F-H) Tumor volume and weight measurements (n = 5). (I-J) IHC staining and GIPC1, TTC7B, and Ki67 positive area of tumor sections from various groups. Scale bar = 50 µm. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. ns: not significant.

Journal: International Journal of Biological Sciences

Article Title: GIPC1 Restrains the Progression and Chemoresistance of Colorectal Cancer by Regulating TTC7B/mTOR/NF-κB Axis

doi: 10.7150/ijbs.119064

Figure Lengend Snippet: The antitumor function of GIPC1-LNPs in chemotherapy-resistant CDX models. (A) Schematic representation of the synthesis of lipid nanoparticles (LNPs) delivering GIPC1 mRNA. (B) Average dimensions, PDI, and zeta potential of GIPC1-LNPs. (C) TEM images of GIPC1-LNPs. Scale bar = 100 nm. (D) Schematic diagram of GIPC1-LNPs treatment in colorectal cancer CDX animal models. (E) Representative images of tumors from each mouse group (n = 5). (F-H) Tumor volume and weight measurements (n = 5). (I-J) IHC staining and GIPC1, TTC7B, and Ki67 positive area of tumor sections from various groups. Scale bar = 50 µm. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. ns: not significant.

Article Snippet: Antibodies for GIPC1, TTC7B, and Ki67 ( GB111499 , Servicebio, China) were applied.

Techniques: Zeta Potential Analyzer, Immunohistochemistry

Quantitative analysis of protein expression in ocular tissues. The percentage of positively stained cells was measured for ( a ) Megalin (LRP2), ( b ) Cubilin (CUBN), ( c ) Caveolin-1 (CAV1), ( d ) GIPC1, and ( e ) DAB2IP in control tissue (ctrl), retinoblastoma (rb), epithelioid melanoma (em), mixoid melanoma (mm), and spindle melanoma (sm). Results are presented as mean ± standard deviation (SD). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. The following symbols indicate levels of statistical significance: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Journal: Cancers

Article Title: Linking Megalin, Cubilin, Caveolin-1, GIPC1 and Dab2IP Expression to Ocular Tumorigenesis: Profiles in Retinoblastoma, Choroidal Melanoma, and the Normal Human Eye

doi: 10.3390/cancers17233785

Figure Lengend Snippet: Quantitative analysis of protein expression in ocular tissues. The percentage of positively stained cells was measured for ( a ) Megalin (LRP2), ( b ) Cubilin (CUBN), ( c ) Caveolin-1 (CAV1), ( d ) GIPC1, and ( e ) DAB2IP in control tissue (ctrl), retinoblastoma (rb), epithelioid melanoma (em), mixoid melanoma (mm), and spindle melanoma (sm). Results are presented as mean ± standard deviation (SD). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. The following symbols indicate levels of statistical significance: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Article Snippet: , Gipc1 Polyclonal antibody , 14822-1-AP , Rabbit , 1:100 , Proteintech Group, Inc., Rosemont, IL, USA.

Techniques: Expressing, Staining, Control, Standard Deviation, Comparison

Immunofluorescence staining of GIPC-1, merged with 4′,6-diamidino-2-phenylindole (DAPI), in control and ocular tumors ( a – e ). Comparative expression of GIPC-1 is shown in control (ctrl; ( a )), retinoblastoma (rb; ( b )), epithelioid melanoma (em; ( c )), mixoid melanoma (mm; ( d )), and spindle melanoma (sm; ( e )). Arrows in the GIPC-1 panels mark areas of notable cytoplasmic signal. In merged panels, arrows show the spatial relationship between GIPC-1 and nuclei. Magnification: 40×; scale bar: 50 µm.

Journal: Cancers

Article Title: Linking Megalin, Cubilin, Caveolin-1, GIPC1 and Dab2IP Expression to Ocular Tumorigenesis: Profiles in Retinoblastoma, Choroidal Melanoma, and the Normal Human Eye

doi: 10.3390/cancers17233785

Figure Lengend Snippet: Immunofluorescence staining of GIPC-1, merged with 4′,6-diamidino-2-phenylindole (DAPI), in control and ocular tumors ( a – e ). Comparative expression of GIPC-1 is shown in control (ctrl; ( a )), retinoblastoma (rb; ( b )), epithelioid melanoma (em; ( c )), mixoid melanoma (mm; ( d )), and spindle melanoma (sm; ( e )). Arrows in the GIPC-1 panels mark areas of notable cytoplasmic signal. In merged panels, arrows show the spatial relationship between GIPC-1 and nuclei. Magnification: 40×; scale bar: 50 µm.

Article Snippet: , Gipc1 Polyclonal antibody , 14822-1-AP , Rabbit , 1:100 , Proteintech Group, Inc., Rosemont, IL, USA.

Techniques: Immunofluorescence, Staining, Control, Expressing

Kaplan–Meier survival curves showing the association between overall survival and the expression levels of Megalin ( LRP2 ) ( a ), Cubilin ( CUBN ) ( b ), Caveolin 1 ( CAV1 ) ( c ), Disabled homolog 2-interacting protein (DAB2IP) ( d ), and GIPC PDZ domain-containing protein 1 ( GIPC1 ) ( e ), in uveal melanoma patients. The analysis was conducted using the publicly available GEPIA2 database ( http://gepia2.cancer-pku.cn/ , accessed 30 July 2025), based on data from The Cancer Genome Atlas (TCGA) Ocular Melanoma (UVM) cohort. Patients were dichotomized into high- and low-expression groups using the median expression value as the cutoff. Solid lines represent survival probability, dotted lines indicate the 95% confidence intervals, and vertical tick marks denote censored cases (patients alive at last follow-up or lost to follow-up).

Journal: Cancers

Article Title: Linking Megalin, Cubilin, Caveolin-1, GIPC1 and Dab2IP Expression to Ocular Tumorigenesis: Profiles in Retinoblastoma, Choroidal Melanoma, and the Normal Human Eye

doi: 10.3390/cancers17233785

Figure Lengend Snippet: Kaplan–Meier survival curves showing the association between overall survival and the expression levels of Megalin ( LRP2 ) ( a ), Cubilin ( CUBN ) ( b ), Caveolin 1 ( CAV1 ) ( c ), Disabled homolog 2-interacting protein (DAB2IP) ( d ), and GIPC PDZ domain-containing protein 1 ( GIPC1 ) ( e ), in uveal melanoma patients. The analysis was conducted using the publicly available GEPIA2 database ( http://gepia2.cancer-pku.cn/ , accessed 30 July 2025), based on data from The Cancer Genome Atlas (TCGA) Ocular Melanoma (UVM) cohort. Patients were dichotomized into high- and low-expression groups using the median expression value as the cutoff. Solid lines represent survival probability, dotted lines indicate the 95% confidence intervals, and vertical tick marks denote censored cases (patients alive at last follow-up or lost to follow-up).

Article Snippet: , Gipc1 Polyclonal antibody , 14822-1-AP , Rabbit , 1:100 , Proteintech Group, Inc., Rosemont, IL, USA.

Techniques: Expressing

Volcano plots showing differential gene expression in two transcriptomic datasets. Differential expression analysis comparing primary human uveal melanocyte cultures (CTRL) and three uveal melanoma cell lines (T115, T142, T143; UVM) from dataset GSE62075 ( a ). Differential expression analysis comparing retinoblastoma tumors (RB) and pediatric control retinae (CTRL) from dataset GSE208143 ( b ). The x-axis represents log2(fold change), and the y-axis represents –log10(adjusted p -value). Each dot represents a gene. Genes with an adjusted p -value less than 0.05 (−log10 > 1.3) are considered significantly differentially expressed and are shown in color: red for upregulated and blue for downregulated genes. Non-significant genes are shown in gray. The positions of Megalin ( LRP2 ), Cubilin ( CUBN ), Caveolin 1 ( CAV1 ), GIPC PDZ domain containing family , member 1 ( GIPC1 ), and Disabled homolog 2-interacting protein ( DAB2IP ) are annotated. In GSE62075 , none of these genes were significantly differentially expressed between CTRL and UVM samples. In contrast, in GSE208143 , LRP2 was significantly downregulated in RB compared to controls, while CUBN , CAV1, GIPC1, and DAB2IP were significantly upregulated in RB tissue.

Journal: Cancers

Article Title: Linking Megalin, Cubilin, Caveolin-1, GIPC1 and Dab2IP Expression to Ocular Tumorigenesis: Profiles in Retinoblastoma, Choroidal Melanoma, and the Normal Human Eye

doi: 10.3390/cancers17233785

Figure Lengend Snippet: Volcano plots showing differential gene expression in two transcriptomic datasets. Differential expression analysis comparing primary human uveal melanocyte cultures (CTRL) and three uveal melanoma cell lines (T115, T142, T143; UVM) from dataset GSE62075 ( a ). Differential expression analysis comparing retinoblastoma tumors (RB) and pediatric control retinae (CTRL) from dataset GSE208143 ( b ). The x-axis represents log2(fold change), and the y-axis represents –log10(adjusted p -value). Each dot represents a gene. Genes with an adjusted p -value less than 0.05 (−log10 > 1.3) are considered significantly differentially expressed and are shown in color: red for upregulated and blue for downregulated genes. Non-significant genes are shown in gray. The positions of Megalin ( LRP2 ), Cubilin ( CUBN ), Caveolin 1 ( CAV1 ), GIPC PDZ domain containing family , member 1 ( GIPC1 ), and Disabled homolog 2-interacting protein ( DAB2IP ) are annotated. In GSE62075 , none of these genes were significantly differentially expressed between CTRL and UVM samples. In contrast, in GSE208143 , LRP2 was significantly downregulated in RB compared to controls, while CUBN , CAV1, GIPC1, and DAB2IP were significantly upregulated in RB tissue.

Article Snippet: , Gipc1 Polyclonal antibody , 14822-1-AP , Rabbit , 1:100 , Proteintech Group, Inc., Rosemont, IL, USA.

Techniques: Gene Expression, Quantitative Proteomics, Control

Multivariate Cox proportional hazards regression analysis of candidate genes in uveal melanoma (TCGA-UVM cohort). Forest plot generated using the kircv3 online platform, showing the hazard ratios (HRs) with 95% confidence intervals (CIs) for the expression of LRP2 , CUBN , DAB2IP , GIPC1 , and CAV1 in relation to overall survival. High expression of DAB2IP was associated with a significantly reduced risk of mortality (protective factor), whereas high expression of GIPC1 was significantly associated with increased mortality risk (adverse prognostic factor). The remaining genes ( CAV1 , CUBN , and LRP2 ) did not reach statistical significance.

Journal: Cancers

Article Title: Linking Megalin, Cubilin, Caveolin-1, GIPC1 and Dab2IP Expression to Ocular Tumorigenesis: Profiles in Retinoblastoma, Choroidal Melanoma, and the Normal Human Eye

doi: 10.3390/cancers17233785

Figure Lengend Snippet: Multivariate Cox proportional hazards regression analysis of candidate genes in uveal melanoma (TCGA-UVM cohort). Forest plot generated using the kircv3 online platform, showing the hazard ratios (HRs) with 95% confidence intervals (CIs) for the expression of LRP2 , CUBN , DAB2IP , GIPC1 , and CAV1 in relation to overall survival. High expression of DAB2IP was associated with a significantly reduced risk of mortality (protective factor), whereas high expression of GIPC1 was significantly associated with increased mortality risk (adverse prognostic factor). The remaining genes ( CAV1 , CUBN , and LRP2 ) did not reach statistical significance.

Article Snippet: , Gipc1 Polyclonal antibody , 14822-1-AP , Rabbit , 1:100 , Proteintech Group, Inc., Rosemont, IL, USA.

Techniques: Generated, Expressing

(A) The CGG repeat is located within exon 1 of GIPC1 . Primers and probes for repeat-primed PCR (RP-PCR, green), fragment analysis (blue), and RNA fluorescence in situ hybridization (FISH, red) were designed within or adjacent to the repeat region. (B) The left panel shows the results for RP-PCR, in which abnormal CGG repeat expansions were detected in the upper three cases. The middle panel displays the results of fragment analysis. The right panel presents histograms of repeat sizes estimated from long-read sequencing data using NanoRepeat; orange bars indicate expanded alleles. (C) Histogram of CGG repeat sizes determined through fragment analysis. The lower graph shows an enlarged view of the low-frequency range. In the control group, most alleles contained 32 or fewer repeats. Two control samples exhibited abnormally expanded alleles, whereas four ALS samples harbored alleles with 33 or more repeats.

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet: (A) The CGG repeat is located within exon 1 of GIPC1 . Primers and probes for repeat-primed PCR (RP-PCR, green), fragment analysis (blue), and RNA fluorescence in situ hybridization (FISH, red) were designed within or adjacent to the repeat region. (B) The left panel shows the results for RP-PCR, in which abnormal CGG repeat expansions were detected in the upper three cases. The middle panel displays the results of fragment analysis. The right panel presents histograms of repeat sizes estimated from long-read sequencing data using NanoRepeat; orange bars indicate expanded alleles. (C) Histogram of CGG repeat sizes determined through fragment analysis. The lower graph shows an enlarged view of the low-frequency range. In the control group, most alleles contained 32 or fewer repeats. Two control samples exhibited abnormally expanded alleles, whereas four ALS samples harbored alleles with 33 or more repeats.

Article Snippet: GIPC1 immunostaining of spinal cord sections from patients with ALS (A) Anterior horn of the lumbar spinal cord from an ALS patient with a CGG repeat expansion stained with anti-GIPC1 antibody (Proteintech). (B) Anterior horn of the lumbar spinal cord from an ALS patient without a CGG repeat expansion stained with anti-GIPC1 antibody (Proteintech). (C) Anterior horn of the lumbar spinal cord from an ALS patient with a CGG repeat expansion stained with anti-GIPC1 antibody (Santa Cruz Biotechnology). (D) Anterior horn of the lumbar spinal cord from an ALS patient without a CGG repeat expansion stained with anti-GIPC1 antibody (Santa Cruz Biotechnology).

Techniques: Fluorescence, In Situ Hybridization, Sequencing, Control

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet:

Techniques:

(A) Results of RNA FISH using a (CGG) 8 probe. Intranuclear RNA foci were observed exclusively in the ALS patient harboring a CGG repeat expansion in GIPC1 . (B) RNA FISH results using another probe targeting the 5′ UTR of GIPC1 . Similar intranuclear RNA foci were detected with this GIPC1 -specific probe, confirming the presence of expanded repeat-containing RNA. Numbers in parentheses indicate the number of CGG repeats in GIPC1 . Scale bars: 5 μm.

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet: (A) Results of RNA FISH using a (CGG) 8 probe. Intranuclear RNA foci were observed exclusively in the ALS patient harboring a CGG repeat expansion in GIPC1 . (B) RNA FISH results using another probe targeting the 5′ UTR of GIPC1 . Similar intranuclear RNA foci were detected with this GIPC1 -specific probe, confirming the presence of expanded repeat-containing RNA. Numbers in parentheses indicate the number of CGG repeats in GIPC1 . Scale bars: 5 μm.

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Techniques: Fluorescence, In Situ Hybridization, Sequencing, Control

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet:

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Article Snippet: Immunoreaction product deposits on immunohistochemically stained sections were visualized using a Histofine Simple Stain MAX-PO MULTI (Nichirei Biosciences, Tokyo, Japan), 3,3′-diaminobenzidine (Nichirei Biosciences), and primary antibodies against phosphorylated TDP-43 (phospho Ser409/410) (clone 11-9, mouse monoclonal, dilution 1:5000, Cosmo Bio Co Ltd, Tokyo, Japan), p62 (clone 3/P62 LCK LIGAND, mouse monoclonal, dilution 1:300, BD Biosciences, San Jose, CA), GIPC1 (rabbit polyclonal, dilution 1:200, Proteintech Group, Chicago, IL), and GIPC1 (clone BG-12, mouse monoclonal, dilution 1:200, Santa Cruz Biotechnologies, Santa Cruz, CA).

Techniques: Fluorescence, In Situ Hybridization, Sequencing, Control

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet:

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Techniques: Fluorescence, In Situ Hybridization, Sequencing, Control

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Figure Lengend Snippet:

Techniques:

Journal: medRxiv

Article Title: GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

doi: 10.1101/2025.05.22.25328088

Techniques:

Review

Structured Review

Images

Similar Products

Image Search Results